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Abstract
Despite the numerous reports of the association of vitamin D with a spectrum of development, disease treatment
and health maintenance, vitamin D deficiency is common. Originating in part from the diet but with a key source
resulting from transformation by exposure to sunshine, a great deal of the population suffers from vitamin D defi-
ciency especially during winter months. It is linked to the treatment and pathogenesis and/or progression of sev-
eral disorders including cancer, hypertension, multiple sclerosis, rheumatoid arthritis, osteoporosis, muscle weakness
and diabetes. This widespread deficiency of Vitamin D merits consideration of widespread policies including
increasing awareness among the public and healthcare professionals.
1. Introduction
Vitamin D is a group of fat-soluble prohormones which
were identified after the discovery of the anti-rachitic
effect of cod liver oil in the early part of the 20
th century.
The vitamin found in cod liver oil was designated “D”
following Vitamin A, B and C, which had been discov-
ered earlier [1]. The two major biologically inert precur-
sors of vitamin D are vitamin D3 (cholecalciferol) and
vitamin D2 (ergocalciferol) [2,3]. Vitamin D3 is formed
when 7-dehydrocholesterol in the skin is exposed to solar
ultraviolet B (UVB, 290-320 nm), and then converted to
previtamin D3. In a heat-dependent process, previtamin
D3 is immediately converted to vitamin D. Excess UVB
rays transform previtamin D3 into biologically inactive
metabolites, tachysterol and lumisterol. Vitamin D2 is
plant derived, produced exogenously by irradiation of
ergosterol, and enters the circulation through diet [1].
Both vitamin D precursors resulting from exposure to
the sunshine and the diet are converted to 25-hydroxyvi-
tamin D [25(OH)D] (calcidiol) when they enter the liver
[4]. 25(OH)D is the major circulating form of vitamin
D and is used to determine vitamin D status. In order to
be biologically active, additional hydroxylation in the
kidneys is needed to form active 1,25-dihydroxyvitamin
D [1,25(OH)2D] (calcitriol) [5]. The process of vitamin D
formation is summarized in Figure 1. Humans obtain
vitamin D through dietary intake and exposure to sun-
light. Very few foods naturally contain vitamin D. Oily
fish such as salmon, mackerel, and sardines are rich in
vitamin D3. Egg yolks are reported to contain vitamin D
though the amounts are highly variable. Moreover, the
cholesterol content of egg yolks makes it a poor source
of vitamin D. Also, a small number of foods are fortified
with vitamin D such as milk, orange juice and some
bread and cereals [6,7]. A list of vitamin D content in dif-
ferent food sources is shown in Table 1.
Vitamin D plays an important role in maintaining an
adequate level of serum calcium and phosphorus. Without
v i t a m i nD ,o n l y1 0t o1 5 %o fdietary calcium and about
60% of phosphorus is absorbed [8-10]. Therefore vitamin
D has a great effect in forming and maintaining strong
bones. It has also recently been found that vitamin D
receptors exist in a variety of cells thus it has a biological
effect on more than mineral metabolism. The aim of this
report is to review key aspects relating to vitamin D defi-
ciency, its causes, and studies on prevention of and treat-
ment of major conditions/diseases. Thus, following a
general literature review on deficiency and its causes, an
overview of major meta-analyses of Vitamin D supplemen-
tation is given. This systematic approach covers meta-
analyses listed in Pubmed during the past 2 decades.
2. Vitamin D deficiency
Vitamin D deficiency and intoxication
Vitamin D deficiency occurs when people do not have
an appropriate dietary intake or exposure to UVB rays.
It is universally accepted that the circulating level of
25-hydroxyvitamin D should be used as an indicator of
vitamin D status due to its ease of measurement, long
half-life in circulation (approximately 2 or 3 weeks),
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states [1,11,12]. Although no consensus on an optimal
level of 25-hydroxyvitamin D has been reached, vita-
min D deficiency is defined by most experts as a level
of less than 20 ng per millilitre (50 nmol per litre)
[13-16]. A level of 25-hydroxyvitamin D of 21 to 29 ng
per millilitre (52 to 72 nmol per litre) is considered as
an insufficiency of vitamin D, and sufficient vitamin D
should reach a level of 30 ng per millilitre or greater
[17].
In 1997, the Institute of Medicine of the US National
Academy of Sciences recommended new adequate
intakes for vitamin D as 200 IU for children and adults
up to 50 years of age, 400 IU for adults 51 to 70 years
of age, and 600 IU for adults 71 years of age or older
[18]. However, a great number of studies revealed that
without adequate sun exposure, children and adults
require approximately 800 to 1000 IU per day [19-22].
Vitamin D intoxication is extremely rare. Studies
showed that doses of more than 50,000 IU per day, which
raises 25-hydroxyvitamin D to more than 150 ng/ml, is
associated with hypercalcemia and hyperphosphatemia
[8,9,23]. Even doses of 10,000 IU of vitamin D3 per day for
up to 5 months did not cause toxicity [24]. However,
Figure 1 Sources, sites, and processing of vitamin D
metabolites.
Table 1 Vitamin D3 and D2 sources and content*
Source Typical Vitamin D content
Natural source
Salmon, fresh, wild (3.5 oz) 600-1000 IU of vitamin D3
Salmon, fresh, farmed (3.5 oz) 100-250 IU of vitamin D3 or D2
Salmon, canned (3.5 oz) 300-600 IU of vitamin D3
Sardines, canned (3.5 oz) 300 IU of vitamin D3
Mackerel, canned (3.5 oz) 250 IU of vitamin D3
Tuna, canned (3.6 oz) 230 IU of vitamin D3
Cod liver oil (1 tsp) 400-1000 IU of vitamin D3
Shiitake mushrooms, fresh (3.5 oz) 100 IU of vitamin D2
Shiitake mushroom, sun-dried (3.5 oz) 1600 IU of vitamin D2
Egg yolk 20 IU of vitamin D3 or D2
Exposure to sunlight, UVB (0.5 MED
†) 3000 IU of vitamin D3
Fortified foods
Fortified butter 50 IU/3.5 oz, usually vitamin D3
Fortified milk 100 IU/8 oz, usually vitamin D3
Fortified orange juice 100 IU/8 oz, vitamin D3
Fortified yogurts 100 IU/8 oz, usually vitamin D3
Infant formulas 100 IU/8 oz, vitamin D3
Fortified margarine 430 IU/3.5 oz, usually vitamin D3
Fortified cheeses 100 IU/3 oz, usually vitamin D3
Fortified breakfast cereals 100 IU/serving, usually vitamin D3
* IU refers to international units, which equal 25 ng.
† About 0.5 MED of UVB radiation would be absorbed after an average of 5 to 10 minutes of exposure (depending on the time of day, season, latitude, and skin
sensitivity) of the arms and legs to direct sunlight.
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cautious with the dose of vitamin D since macrophage
production of 1,25-dihydroxyvitamin D causes hypercalce-
mia and hyperphosphatemia [8,9,23].
2.1 Causes of vitamin D deficiency
There are many causes of vitamin D deficiency. Gener-
ally, they can be divided into two groups: UVB-related
deficiency and medical/physical condition-related
deficiency.
2.1.2 UVB-related deficiency
The elderly The elderly, due to the decreased presence
of skin 7-dehydrocholesterol which is the precursor for
UVB mediated synthesis of vitamin D, are particularly
at risk of vitamin D deficiency. Moreover, reduced
mobility or institutionalization that discourages sun
exposure, reduced renal production of 1,25-dihydroxy-
vitamin D as well as decreased intake of fortified foods
pose great difficulties in vitamin D formation in body
[25,26].
Dark skin People with dark skin have great amounts of
melanin in their epidermis. Melanin competes with
7-dehydrocholesterol for absorption of UVB photons.
Therefore, people of color are less efficient in produ-
cing vitamin D than are whites. It is reported that a
person with skin type 5/6 (dark skin) requires 10-50
times the exposure to sunlight to produce the same
amount of vitamin D as does a white person with skin
type 2/3 [27].
Season, latitude, and the time of day It has been
established that the ozone layer can absorb UVB radia-
tion above 290 nm which is responsible for generating
previtamin D3. Zenith angle, defined as the angle of the
sunlight reaching the Earth’s surface, decides the thick-
ness of ozone layer which sunlight needs to penetrate.
The thicker the ozone layer is, the fewer amounts of
UVB photons can reach the earth, thus few previtamin
D3 can be produced. Zenith angle is dependent on
factors such as time of day, season of the year, and lati-
tude. Thus those factors have great effects on vitamin D
production [28,29]. For example, residents of Boston
( 4 2 ° N ) ,E d m o n t o n ,C a n a d a( 5 2 ° N )a n dB e r g e n ,N o r w a y
(61°N) can not produce sufficient quantities of vitamin
D in their skin for 4, 5, and 6 months, respectively [6].
Sunscreen users Sunscreens can efficiently absorb UVB
radiation. This dramatically prevents the interaction of
UVB with 7-dehydrocholesterol, the process of previta-
min D3 generation. It has been shown that when used
properly, a sunscreen with a sun protection factor of 8
reduces the production of previtamin D3 by 95%, and
99% by a sun protection factor of 15 [30,31].
2.1.2 Medical/physical condition-related deficiency
Fat malabsorption As a fat-soluble vitamin, vitamin D
requires the presence of di e t a r yf a ti nt h eg u tf o r
absorption. Certain pathological conditions, such as
Crohn’s disease, cystic fibrosis (CF), celiac disease, surgi-
cal removal of part of the stomach or intestines are
associated with fat malabsorption and thus may lead to
vitamin D deficiency. For example, CF patients suffer
from pancreatic exocrine insufficiency. This results in
malabsorption of fat-soluble vitamins, including vitamin D.
CF patients, depending on the degree of exocrine insuffi-
ciency, absorb approximately 50% less vitamin D than
normal [32].
Anticovulsant use Anticonvulsants, also called antiepi-
leptic drugs, have been used to treat epileptic seizures and
bipolar disorder. It is well recognized that long-term use
of some antiepileptic drugs, including phenobarbital,
phenytoin, and carbamazepine and the antimicrobial agent
rifampicin (RIF) can result in osteomalacia [33-37]. The
induction of the catabolism of 1,25-dihydroxyvitamin D by
these drugs is thought to contribute to their deleterious
side effects.
Chronic kidney disease In order to become biological
active vitamin D, kidney plays an important role in this
transforming process. Chronic kidney disease such as
patients with stage 4 or 5 chronic kidney disease, as well
as those requiring dialysis, leads to an inability to make
sufficient 1,25-dihydroxyvitamin D which has a direct
effect in inhibiting parathyroid hormones expression
[38,39]. Thus 1,25-dihydroxyvitamin D3 intake is needed
to maintain calcium level in blood as well as to control
parathyroid hormone levels.
Obesity It has been known for a long time that obese
people are prone to be vitamin D deficient since they
have lower 25-hydroxyvitamin D levels [40-43].
A number of studies proved that the vitamin D3
precursor 7-dehydrocholesterol levels in the skin of
obese people were not significantly different from non-
obese people [26,44]. One explanation was that the
subcutaneous fat, which is known to store vitamin D,
sequestered more of the cutaneous synthesized vitamin
D, which results in less release of vitamin D from the
skin into the circulation in the obese subject than
non-obese subject [45].
Epidemiology of vitamin D inadequacy
Several studies showed that 40 to 100% of U.S. and
European elderly men and women still living in the
community (not nursing homes) are deficient in vitamin
D [13-15]. It has already become a largely unrecognized
global epidemic. Vitamin D inadequacy can be seen in
young adults as well as healthy children. For example,
48% of white preadolescent girls in a study in Maine
[46] and 52% of Hispanic and black adolescents in a
study in Boston are vitamin D deficient [47]. In Europe,
where very few foods are fortified with vitamin D, chil-
dren and adults would appear to be at especially high
risk [48-50]. A study of middle aged British adults
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number rose to 90% during winter and spring [51].
3. UVB in vitamin D formation
The resurgence of vitamin D deficiency has been
attributed to the lack of exposure to sunlight that has
been a growing concern in the past few decades owing
to associations with skin cancer. From this standpoint,
along with the modern predominance for indoor living
and working, it is apposite to look at photo-induced
vitamin D activation. In future we may replace artificial
light with a form that is more efficient at meeting our
requirements for vitamin D. Ultraviolet (UV) rays are
electromagnetic waves with wavelength of between 400
nm and 10 nm. UV can be divided into three compo-
nents according to wavelength: UVA (320-400 nm),
UVB (290-320 nm), and UVC (100-290 nm). They have
different skin penetration abilities, and generate different
biological effects.
UVB plays a key role in vitamin D formation. It is
absorbed by the epidermal layer, where the highest con-
centration of 7-dehydrocholesterol exists. It has been
found that the optimum wavelength range for the pro-
duction of vitamin D is between 295 and 300 nm. This
narrow range is sometimes referred to as D-UV [52]. As
vitamin D is rare in the diet consumed by human
beings, the major source of vitamin D is exposure to
sunlight, particularly the UVB component [23,53,54].
Another advantage of UVB exposure in formation of
vitamin D is that UVB exposure does not result in
excessive production of vitamin D, which causes risks of
intoxication. This can be explained that the previtamin
D3 that is formed and the thermal isomerization
product vitamin D3 that does not go into the circulation
absorb UVB radiation and isomerize to several photo-
products which have little activity on calcium metabo-
lism [55].
Choice of wavelength
As UVB exposure is not associated with vitamin D
intoxication, the major concern of using UVB to boost
vitamin D content is the erythema reaction, which is a
result of cell irritation and destruction caused by ultra-
violet radiation. In the UVB region, the wavelength
range between 290 and 297 nm has the greatest
erythema effect on the human body with a steep
decrease above 297 nm. Therefore UVB tubes with
spectral features of minimal irradiance from 290 to 297
nm should always be chosen to treat vitamin D
deficiency.
The duration of exposure
The duration of exposure determines the dose of UVB
one receives. The product of the UVB lamp power output
(mW/cm
2)a n dt h ed u r a t i o no fe x p o s u r ei sU V Br a d i a -
tion (mJ/cm
2). Minimal erythema dose (MED) is defined
as the minimum amount of UVB radiation that produces
redness 24 hours after exposure. It is used when using
UVB to treat psoriasis in order to minimize the potential
for developing erythema. Therefore the radiation should
not be more than one MED for safety considerations
when treating vitamin D deficiency. Thus, a limit should
be put on exposure time depending on power output.
It should be noted that MED varies with skin type
(Table 2) and there are large variations in MED even
within the same skin type [56]. According to the U.S.
Food and Drug Administration and the American Acad-
emy of Dermatology, there are six skin-type categories:
skin type I-VI. Generally the darker the skin, the harder
it is for the skin to burn, thus the higher the value of
MED which results in a longer exposure duration to
achieve a certain value of MED.
3.1 Vitamin D production
It has been reported that exposure of 6-10% of the body
surface to 1 MED is equivalent to ingesting about 600-
1000 IU of vitamin D [57]. In general, when using UVB
radiation in vitamin D formation, the factors influencing
vitamin D production can be summarized as: the UVB
r a d i a t i o n ,t h ee x p o s u r ed u r a t i o na n db o d ye x p o s u r e
area. The stronger the radiation is (under certain limits),
the longer the exposure duration is (under certain
limits), the larger the body exposure area is, the more
vitamins can be produced.
A number of studies have been conducted to improve
vitamin D content using UVB rays [58-61]. 45 female
psychogeriatric patients in nursing homes received 1/2
MED UVB irradiation, three times per week, for
12 weeks. Results showed that 1,25-dihydroxyvitamin D
levels increased significantly from 30 nmol/l to 60 nmol/l
on average [62]. Another study using UV light to treat
vitamin D deficiency resulted from malabsorption indi-
cated that 25-hydroxyvitamin levels increased by 28% at
the end of 8 weeks [63].
3.2 Contraindications
UVB irradiation does not appear to suit some indivi-
duals who develop headache, nausea and possibly vomit-
ing and rise of temperature after exposure. Also people
with sensitive skin may react strongly to UV rays, thus
are unsuitable for UV treatment [64].
Certain drugs could make individuals become more
susceptible than normal to the effects of UV radiation,
examples being gold, the sulphonamides, insulin, thyroid
extract, and quinine. Therefore UVB should not be used
in conjunction with these drugs. An area which has
recently been subjected to doses to X-rays is not suita-
ble for UVB treatment since it may cause carcinoma of
the skin. UV may also cause the aggravation of certain
diseases such as pulmonary tuberculosis, acute eczema
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UVB in these conditions.
3.3 Vitamin D intake in different conditions
The association of low status of vitamin D with several
diseases has been long established. Increasing vitamin D
levels through oral supplementation or sunlight expo-
sure is vital in the management of these conditions.
Also, vitamin D has been used to treat some minor
abnormalities, such as tooth loss and depressed moods,
in order to maintain a healthy lifestyle. Moreover,
research during the past two decades has highlighted
the important role of vitamin D in reducing the risks of
a series of conditions including cancer, multiple sclero-
sis, hypertension, to name a few. In this section, the uti-
lity of vitamin D for different purposes such as disease
management, prevention, and improvement of quality of
life will be discussed.
4. Disease management
A large number of trials have been conducted over the
past two decades into the effects of vitamin D on
disease management and prevention. The efficacies of
vitamin D, as demonstrated by the meta-analyses
reported in this period, are largely unconvincing apart
from in relation to falls and fractures in the elderly.
These meta-analyses, summarized in Table 3 do not
show a substantial role for vitamin D either through
prevention or treatment of many conditions for which it
is associated. It should be noted that many of the meta-
analysis relied on disparate studies which introduces sig-
nificant questions regarding the results. Despite this
overview, and in a somewhat unorthodox approach
some key studies will be discussed below that may lead
to more focused and appropriate trials.
Osteoporosis
Approximately 33% of women aged between 60 to 70
and 66% of those over 80 have osteoporosis [13]. The
link between vitamin D deficiency and osteoporosis has
been well established especially in the elderly. Vitamin
D deficiency is associated with the marked suppression
in intestinal Ca absorption and the impairment of Ca
balance, which results in low bone mineral content and
density. Reduced bone mineral density (BMD) increases
the risk of fractures, which significantly contributes to
morbidity and mortality of older persons [65,66]. Hip
fracture is expected to be more prevalent worldwide
with the increase in aging of the population, and the
consequences are severe: 50% of older persons have per-
manent functional disabilities, 15% to 25% require long-
term nursing home care, and 10% to 20% die within
1 year.
The efficacy of vitamin D as a prevention of fracture
has been demonstrated by a number of studies. Trials
using 700 to 800 IU/d oral vitamin D with or without cal-
cium supplementation found a significant 26% reduction
in risk of sustaining a hip fracture and a significant 23%
reduction in risk of sustaining any non-vertebral fracture
versus calcium or placebo [67]. Also, a 3-year French
study of 3270 elderly women (mean age 84 years) living
in care home, where vitamin D deficiency is prevalent,
indicates that calcium (1200 mg daily) and vitamin D
(800 IU daily) can reduce the probability of hip and all
non-vertebral fractures by 43% and 32%, respectively,
compared with placebo [68,69]. Conversely, a Dutch
study of 2578 healthy elderly women treated with a high
calcium intake, daily supplementation with vitamin D
400 IU over 3.5 years showed no effect on the risk of hip
fracture [70]. Therefore, whether 400 IU vitamin D is
enough to prevent fracture in healthy elderly subjects
with normal BMD needs further investigation.
Muscle weakness
Muscle weakness is also a prominent feature of vitamin
D deficiency. Patients with nonspecific muscle weakness,
muscle aches and pains have also been found with vita-
min D inadequacy [71,72]. Impaired muscle function is
known to cause an increased number of falls which can
lead to hip fractures. The incidence of falls go up sub-
stantially in those older than 70 years of age, and over
90% of hip factures resulted from a fall. It has been
established that skeletal muscle tissue contains vitamin
D receptor and may require vitamin D to realize maxi-
mum function [23,73].
Table 2 Skin type categories from Food and Drug Administration (FDA) and the American Academy of Dermatology
Skin types Sun history Example
I Always burns easily, never tans, extremely sensitive skin Red-headed, freckled, Celtic, Irish-Scots
II Always burns easily, tans minimally, very sensitive skin Fair-skinned, fair-haired, blue-eyed Caucasians
III Sometimes burns, tans gradually to light brown, sun-sensitive skin Average-skinned Caucasians, light-skinned Asians
IV Burns minimally, always tans to moderate brown, minimally sun-sensitive Mediterranean-type Caucasians
V Rarely burns, tans well, sun-insensitive skin Middle Easterners, some Hispanics, some African-Americans
VI Never burns, deeply pigmented, sun-insensitive skin African-Americans
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can improve muscle performance, and thus reduce the
incidence of fall. In a 5-month randomized controlled
trial, elderly people in a nursing home received 800 IU
of vitamin D2 plus calcium daily, exhibited a 72% reduc-
tion in the risk of falls as compared with the placebo
group [74]. Long-term intake of 700 IU vitamin D plus
500 mg of calcium in 246 community-dwelling older
women also showed a beneficial reduction falls: the
odds of falling declined by 46% compared with the pla-
cebo group [74]. However, the results from one trial
suggested that 400 IU vitamin per day may not be clini-
cal effective in preventing falls in the elderly [75].
Hypertension
Millions of people are affected by hypertension
worldwide. Growing evidence in recent years suggests
that vitamin D has an important association with
blood pressure. Animal experiments implicate 1,25-
dihydroxyvitamin D in inhibiting renin expression in
the juxtaglomerular apparatus and blocks proliferation
of vascular smooth muscle cells (VSMC), which could
influence systemic blood pressure [76-79]. Studies
showed that Afro-Americans have a significantly
higher prevalence of diastolic hypertension [80] and
have lower 25-hydroxyvitamin D levels [81] compared
with white Americans.
Reduced blood pressure has been found in people tak-
ing oral supplementation of vitamin D. In humans, skin
exposure to UVB, which is the major source of vitamin
D formation, has been linked with lower blood pressure
[82-84]. An 8-week single intervention study of 148
vitamin D deficient elderly women demonstrated a 9%
decrease in systolic blood pressure with supplemental
vitamin D (800 IU) plus calcium (1200 mg) compared
with calcium alone [85]. In another study, patients with
hypertension were exposed to UVB radiation three
times a week for 3 months. Results showed that 25-
hydroxyvitamin D levels increased by approximately
180%, and both systolic and diastolic blood pressure
reduced by 6 mm Hg [84]. In contrast, a large prospec-
tive study of men and women found no association
between intake of vitamin D from diet and supplements
and hypertension incidents [86]. This difference may be
attributed to the fact that the large observational study
included subjects from the general public while other
Table 3 Systematic reviews on Vitamin D for prevention or treatment (in chronological order)
Area Number
of studies
Type Doses Conclusion Reference
Cardiovascular events 17 Prospective ~1000IU S not SS 162
Cardiometabolic outcomes 31 Observ/Trial Range No effect 163
Fracture prevention 7 Randomised 10-20 mcg
+C a
No effect
Reduced risk
164
164
Physical performance 8
8
Observational
Intervention
-
-
Positive (5/8)
Mixed
165
165
Kidney disease
(-dialysis)
16 RCT - Uncertain 166
Kidney disease (+dialysis) 60 RCT - Uncertain 167
Cystic fibrosis 3 (q)RCT 800-1600IU No effect 168
Risk of falling 8 RCT 700-1000IU
200-600IU
Reduced risk
No effect
169
169
Hypertension 11 RCT - S - SS 170
Risk of falling 111* RT or interv. - No effect 171
Fracture prevention 45 (q)RCT -
+Ca
No effect
S not SS
172
172
Risk of Type 1 diabetes 5 Observational - Uncertain 136
Parathyroid hormone 52 Intervention _ Decrease 173
Mortality 18 RCT 2300-2000IU Uncertain 174
Risk of fall/fracture 9 - - Decrease (trend) 175
Risk of fracture 12 RCT 700-800IU
400IU
Decrease (trend)
No effect
176
176
Risk of fall 10 RCT - Decrease 177
Bone density Fracture 17
17
RCT
RCT
-
-
Uncertain
Reduction
178
S not SS: Small effect - not statistically significant (sub-groups are discounted); RCT: Randomised controlled trial {(q) - quasi}; * Multiple factor study.
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nal vitamin D levels could have certain impacts on treat-
ment effect.
Multiple sclerosis
Multiple sclerosis (MS) is an autoimmune disease in
which the body’s immune system attacks myelin, a key
s u b s t a n c et h a ts e r v e sa san e r v ei n s u l a t o ra n dh e l p si n
the transmission of nerve signals. It has been long
recognised that MS is more common in temperate cli-
mates than the tropics [87,88], and annual and winter
hours of sunlight have been proved to have the stron-
gest negative correlation with the prevalence of MS
[89,90]. One explanation is that the increase of vita-
min D results from sunlight exerting a protective
effect [91-93]. Studies also found that individuals with
MS tend to have insufficient vitamin D levels
[71,94-97].
However, only a few reports are available on the use of
vitamin D in treating MS patients. One study (6 months)
of the cytokine profile in MS patients with vitamin D
(1000 IU/day) and calcium (800 mg/day) showed that
25-hydroxyvitamin D significantly increased from 42.5 ±
15 to 70 ± 20 nmol/l. Also vitamin D supplementation
significantly increase serum transforming growth factor
(TGF)-b1, which has been shown to be an important
anti-inflammatory cytokine in animal models of MS [98].
The increased TGF-b1 suggests that vitamin D supple-
mentation could potentially improve the symptoms of
MS patients. Nonetheless, more studies are needed to
establish vitamin D’s efficacy in alleviating MS.
A p a r tf r o mi m p r o v i n gM Sp a t i e n t s ’ health conditions,
vitamin D has also been shown to have effects in pre-
venting MS. One study revealed that women who used
supplemental vitamin D (> 400 IU/day) had a 40% lower
risk of MS than women who did not use vitamin D [99].
Another report among 7 million US military personnel
reported that risk of MS decreased with increasing
25-hydroxyvitamin D which provided an evidence of
vitamin D’s protective role in MS developing [100].
Malabsorption
As explained above, certain conditions cause malabsorp-
tion, which results in vitamin D deficiency. Low BMD
can be frequently found in these conditions. Thus vita-
min D supplementation is required to boost vitamin D
sera levels. For example, Cystic fibrosis (CF) patients
have inefficient vitamin D absorption due to pancreatic
exocrine insufficiency. It is reported that 95% of a trea-
ted cohort of CF patients required 1800 IU (45 μg/d or
0.13 mmol) of ergocalciferol (vitamin D2) daily to
achieve a 25OHD concentration above 25 ng/ml [101].
Vitamin D deficiency is prevalent in Crohn’s Disease
(CD). CD is an inflammatory bowel disease which often
leads to osteopenia and osteoporosis due to malabsorp-
tion of vitamin D. One study conducted on 154 CD
patients for 76 days showed that daily calcium (500 mg)
and vitamin D (400 IU) supplementation was associated
with an increase in bone mineral density [102].
5. Vitamin D associations with disease prevention
Rickets
With the re-arrival of widespread vitamin D deficiency,
t h er e - e m e r g e n c eo fr i c k e t s ,as c o u r g ef r o mt h en i n e t i -
eth century was inevitable. In a recent review, the
deficiency rates found in countries where extreme sun-
light levels are readily available but people are covered
or avoid sunlight and do not have access to vitamin
D-fortified foods [23]. Insufficient levels of vitamin D in
breastfeeding mothers can, often unknowingly, lead to
deficiencies in children. It is suggested that a supple-
ment level of 400IU/d for infants as practiced in Canada
is optimal [23].
Cancer
The first study indicating that sunlight exposure may
lower the risk of cancer was first made almost seven
decades ago [103]. Garland and Garland were the first
to propose that vitamin D deficiency may contribute to
a higher risk of colon cancer mortality since vitamin D
is formed in the skin through solar UVB radiation.
More recently, the discovery of increased risks of certain
types of cancer in those who are vitamin D deficient,
suggests that vitamin D deficiency may account for
thousands of premature deaths from colon [104], breast
[105,106], ovarian [107], and prostate cancer [108] every
year.
Vitamin D is one of the most potent hormones for
regulating cell growth. It was discovered that many cell
types contain vitamin D receptors. These receptors can
be activated by 1,25(OH)2 D, and induce differentiation
into normally functioning cells, and inhibit proliferation,
invasiveness, angiogenesis, and metastatic potential. In
tumor models such as cancers of the lung [109-111],
colon [112], kidney [113], breast [114], and prostate
[115], vitamin D played a role in activity against
metastasis [116-120].
The protective relationship between sufficient vitamin
D status and lower risk of cancer has been found in
many studies. It has been reported that breast and color-
ectal cancer can be reduced by 50% with the concentra-
tion of 25-hydroxyvitamin D being >32 ng/mL [121,122].
A similar study of colorectal cancer found that a level of
34 ng/mL 25-hydroxyvitamin D can reduce the incidence
by half, and 46 ng/mL can decrease it by two thirds
[123]. A 4-year trial on postmenopausal women showed
that 1100 IU/day vitamin D plus 1400-1500 mg/day cal-
cium can substantially reduces all-cancer risk [121].
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RA is an autoimmune disorder of unknown etiology in
which both genetic and nongenetic factors contribute to
disease susceptibility [124]. The immunomodulatory
effect of Vitamin D has received increasing attention in
recent years. Studies showed that when confronted
by an inappropriate and overly exuberant immune
response, vitamin D may act in a paracrine manner to
decrease T cell responsiveness through the inhibition of
cellular proliferation and reduction in lymphokine pro-
duction [125-128]. Therefore vitamin D has a beneficial
effect as an immunosuppressant.
Vitamin D has shown its ability to suppress the devel-
opment of autoimmunity in animal experiments. For
example, murine models of human RA demonstrated
that when treated with active vitamin D, both the inci-
dence and severity of the disease in mice decreased
[129]. However the association of vitamin D intake and
RA incidence in humans has not been well studied. One
study of 30,000 women aged 55 to 69 over 11 years
observed an inverse association between greater intake
of vitamin D and RA risk [130]. Interestingly, vitamin D
from supplements showed a stronger influence in RA
development than did dietary vitamin D. However,
further studies are needed to establish the effect of
vitamin D in the prevention of RA.
Diabetes
A diabetes epidemic has emerged during the 20
th cen-
tury. The prevalence of diabetes for all age groups was
estimated to be 2.8% in 2000, and this number will
increase to 4.4% by 2030 [131]. It has been reported as
early as the 1980 s that vitamin D deficiency inhibits
pancreatic secretion and turnover of insulin, resulting in
impaired glucose tolerance [132,133]. An association
was found between low UVB irradiance, indicating a
low level of vitamin D, and high incidence of type 1 dia-
betes, whereas the incidence rate approached zero in
regions with high UVB irradiance [134-137].
A study of 83,779 women with no history of diabetes
over 2-4 years showed that a combined daily intake of
>1200 mg calcium and >800 IU vitamin D was asso-
ciated with 33% lower risk of type 2 diabetes as com-
pared with a daily intake of less than 600 mg of calcium
and less than 400 IU of vitamin D [138]. Another study
on 10,366 children in Finland over 31 years indicated
that 2000 IU of vitamin D per day during their first year
of life can reduce the risk of type 1 diabetes by approxi-
mately 80% [139].
Tuberculosis (TB)
TB is a major global problem and responsible for 2 mil-
lion deaths a year. It is estimated that one-third of the
global population has latent TB infection [140], which
poses great potential risks of reactivation in the future.
In fact, before antibiotics came in to use, high doses of
vitamin D were widely used to treat active TB [141].
Cross-sectional studies showed that patients with TB
have lower 25(OH)D levels in comparison with control
subjects [142,143]. Recently, it was found that low vita-
min D status resulting from a vegetarian diet is an inde-
pendent risk factor for active TB in South Asians [144].
Until now studies evaluating the effect of vitamin D
on the body’s immunity to mycobacteria, the family of
bacteria that cause TB, are scanty. One study measuring
192 healthy adult TB contacts’ showed that a single oral
dose of 2.5 mg vitamin D significantly enhanced partici-
pants’ whole blood ability to restrict functional whole
blood (BCG-lux) luminescence in vitro [145]. It con-
cluded that vitamin D enhances TB contacts’ immunity
to mycobacteria. However, the effect of vitamin D sup-
plementation on TB incidence rates among deficient
population with high rates of latent TB infection should
be investigated to determine vitamin D’sp r e v e n t i o n
effect in TB.
6. Health maintenance and Vitamin D
Besides treating and preventing a range of disease, vita-
min D has also been applied in managing minor
abnormalities so as to improve quality of life.
Periodontal disease is a common chronic inflamma-
tory disease characterized by loss of periodontal attach-
ment. It is the leading cause of tooth loss [146-150]
which has a great impact in nutrient intake the quality
of life [151-153]. Several epidemiologic studies revealed
that there is link between osteoporosis and tooth loss,
which indicate that the cause of osteoporosis could also
contribute to periodontal disease. A 3-year study
showed that supplementation with vitamin D (700 IU/d)
plus calcium (500 mg/d) significantly reduced tooth loss
in older people [154].
Mood changes with season, a common phenomenon
is that anxiety and depression increase during winter
months. An extreme case of this seasonality is a clinical
syndrome called seasonal affective disorder (SAD), also
known as winter depression. One explanation is the
changing level of vitamin D3 during winter. One study,
including 44 healthy subjects during winter, investigated
the efficacy of vitamin D3 in enhancing mood. Results
on a self-report showed that vitamin D3 significantly
enhance positive affect [155].
Vitamin D has also been found to play an important role
in brain development and function [156-159]. The study
pointed out the wide distribution of vitamin D receptors
throughout the brain. It showed that vitamin D has the
ability to affect proteins which are known to be directly
involved in learning and memory, motor control, and pos-
sibly even maternal and social behavior [160]. Maintaining
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the normal receptor transcriptional activity in the brain.
This may be vital for brain development and also the
maintenance of mental function later in life [161].
As shown in Table 3 the postulated efficacies of vita-
min D, as demonstrated by the meta-analyses reported
are largely unconvincing for most diseases/conditions
apart from in relation to falls and fractures in the elderly
[162-178]. Despite considerable efforts to explore the
benefits of vitamin D, little convincing evidence has
been presented in the form of meta-analyses in relation
to the cardiovascular system, kidney function, Cystic
fibrosis, diabetes, and mortality. The meta-analyses
relied on disparate studies with varied approaches to
measuring vitamin D analogues which may introduce
significant questions regarding the results. It is sug-
gested that further standardization should be introduced
regarding which forms of vitamin D are measured and
how they are measured.
Conclusions
Vitamin D inadequacy is a global problem. Approxi-
mately 36% of otherwise healthy young adults and up to
57% of general medicine inpatients in the United States
suffer from vitamin D inadequacy. These figures are
even higher in Europe [71].
In the past, vitamin D intake was associated with the
prevention of rickets in children whereas its effect in
other areas has received little attention. In recent years,
vitamin D deficiency has also been linked with the
pathogenesis and/or progression of several disorders,
including cancer, hypertension, multiple sclerosis, dia-
betes although the evidence for the associations of vita-
min D with these conditions is generally weaker than it
is for bone-related disease.
Although recommendations of daily vitamin D intake
have been provided, higher levels are required in order
to have real preventive or treatment effects as numerous
studies have proved. UVB radiation plays an alternative
in improving vitamin D content other than oral supple-
mentation. Its advantage is that it will not cause vitamin
D intoxication since excessive vitamin D will be broken
down by UVB. However, a number of factors of the
UVB such as wavelength, duration of exposure are
needed to be carefully controlled so as to avoid
erythema.
Despite the close link of vitamin D with human
health, vitamin D inadequacy is not widely recognized
as a problem by physicians and patients. Greater aware-
ness of this problem is required among researchers, clin-
ician, and patients of the high prevalence of vitamin D
inadequacy.
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